Zoetis Inc. with ticker code (ZTS) have now 13 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $260.00 and $200.00 calculating the average target share price we see $226.31. (at the time of writing). Given that the stocks previous close was at $184.08 and the analysts are correct then there would likely be a percentage uptick in value of 22.9%. The 50 day MA is $192.27 and the 200 moving average now moves to $179.97. The company has a market cap of 86.83B. The current share price for the company is: $189.65 USD
The potential market cap would be $106,755,274,696 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 37.48, revenue per share of $18.53 and a 13.15% return on assets.
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. It commercializes products across eight core species: dogs, cats and horses and cattle, swine, poultry, fish and sheep and within product categories, such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company operates through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The Company market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company’s products are sold in more than 100 countries.
